Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Why Kymera Therapeutics Stock Crushed It This Week
Kymera Therapeutics to Unveil New Oral Development Candidate
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Here's Why We're Watching Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Kymera Therapeutics Initiates Dosing In BroADen Phase 1B Clinical Trial Evaluating KT-621, Potent Degrader Of STAT6, In Patients With Moderate To Severe Atopic Dermatitis
Express News | Kymera Therapeutics Inc - Phase 2B Trials in Ad and Asthma to Start in 4Q25 and 1Q26
Express News | Kymera Therapeutics Inc - KT-621 Phase 1 Healthy Volunteer Trial Data Expected in June 2025
Express News | Kymera Therapeutics Announces First Patient Dosed in Broaden Phase 1B Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral Stat6 Degrader
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
Press Release: Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $49
Citi Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Raises Target Price to $52
Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target
TD Cowen Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Kymera Therapeutics (KYMR) and Anika Therapeutics (ANIK)
Leerink Partners Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $60
Kymera Therapeutics: Promising Prospects in STAT6 Targeting With KT-621